Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63,525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, Ning Y, Gandhi AK, Daniel TO, Chopra R, Klippel A, Thakurta AG. Bjorklund CC, et al. Among authors: wang m. Blood Cancer J. 2015 Oct 2;5(10):e354. doi: 10.1038/bcj.2015.66. Blood Cancer J. 2015. PMID: 26430725 Free PMC article.
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, García-Gómez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF. Ocio EM, et al. Among authors: wang m. Leukemia. 2015 Mar;29(3):705-14. doi: 10.1038/leu.2014.238. Epub 2014 Aug 8. Leukemia. 2015. PMID: 25102946
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Kuhn DJ, et al. Among authors: wang h, wang m. Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29. Blood. 2012. PMID: 22932796 Free PMC article.
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.
Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Kuiatse I, et al. Among authors: wang m. Clin Cancer Res. 2015 Jun 1;21(11):2538-45. doi: 10.1158/1078-0432.CCR-14-1462. Epub 2015 Mar 6. Clin Cancer Res. 2015. PMID: 25748087 Free PMC article.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Avet-Loiseau H, et al. Among authors: wang m. Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. Epub 2016 Jul 20. Blood. 2016. PMID: 27439911 Free PMC article. Clinical Trial.
NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.
Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L. Li Y, et al. Among authors: wang f, wang m. Blood Cancer J. 2017 Nov 23;7(12):632. doi: 10.1038/s41408-017-0005-z. Blood Cancer J. 2017. PMID: 29167454 Free PMC article. No abstract available.
63,525 results
You have reached the last available page of results. Please see the User Guide for more information.